Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics is hosting a virtual key opinion leader webcast to discuss ATH434 for treating Multiple System Atrophy (MSA), a rare, rapidly progressive neurodegenerative disease with no approved treatment. The event will feature neurologists Roy Freeman, MD, and Daniel Claassen, MD, MS, alongside CEO David Stamler, MD.
The company describes ATH434 as its lead asset and notes that it has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA, with additional positive data from an open label Phase 2 study in advanced MSA. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA and continues to develop a broader drug discovery platform targeting the underlying pathology of neurodegenerative diseases.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan has filed an initial Form 3 showing his indirect holdings in the company. The filing reports 4,545,455 ordinary shares held indirectly through Montoya Pty Ltd <Buttercup A/C>.
He also indirectly holds listed options over 1,515,152 ordinary shares with a conversion price of $0.028 per share, expiring on 26 February 2027, and unlisted options over 50,000,000 ordinary shares with a conversion price of $0.010 per share, expiring on 30 December 2027. The Form 3 records these positions as existing holdings rather than new market purchases or sales.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy filed an initial Form 3, which is a required disclosure of insider holdings. The filing lists him as a director but shows no reportable transactions, exercises, gifts, or restructurings and no derivative positions in this snapshot.
Alterity Therapeutics director Peter Ashley Marks filed an initial Form 3 reporting his beneficial holdings in the company. He indirectly holds 1,818,182 Ordinary shares through Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>. He also holds listed options over 606,061 Ordinary shares with a conversion price of $0.028 per share expiring on 26 Feb 2027, and unlisted options over 30,000,000 Ordinary shares with a conversion price of $0.010 per share expiring on 30 Dec 2027.
Alterity Therapeutics Chief Financial Officer Abby Sarah Macnish Niven filed an initial ownership report detailing indirect equity interests in the company held through CASAM Investments Pty Ltd.
The filing lists 454,545 ordinary shares and a listed option expiring on 26 Feb 2027 over 151,510 underlying ordinary shares at an exercise price of 0.0280 per share. These entries describe existing indirect holdings rather than new market purchases or sales.
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA). After a Type C Meeting, the FDA provided written feedback supporting the company’s clinical pharmacology and non-clinical plans for a planned Phase 3 pivotal trial.
The company now aims to secure FDA agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-year 2026. ATH434 has already shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and additional positive data in an open-label Phase 2 study in advanced MSA, and Alterity is preparing to initiate Phase 3.
Alterity Therapeutics Limited has reported a proposed issue of 150,000,000 options as payment for services to Lawrence Gozlan and Chairman Julian Babarczy. The options have an exercise price of A$0.02 and expire five years after issue, with an expected expiry date of 26/6/2031.
The options are to be issued for non-cash consideration, with each option exercisable into one fully paid ordinary share. The proposed issue date is 26/6/2026 and is subject to shareholder approval at a meeting scheduled for 27/5/2026 under ASX Listing Rule 7.1.
Alterity Therapeutics Limited is introducing an opt-out unmarketable parcel sale facility for shareholders holding less than A$500 in fully paid ordinary shares. Using the 9 March 2026 closing price of $0.008, this equates to holdings of fewer than 62,500 shares.
About 5,868 shareholders are on the register, of which approximately 59.2% hold an unmarketable parcel. These shareholders can either do nothing and have their shares sold without brokerage, or retain their holding by returning a Share Retention Form or increasing their holding to at least 62,500 shares by 7.00pm (AEST) on 24 April 2026.